Content deleted Content added
m Moving from Category:Chloroarenes to Category:Chlorobenzenes using Cat-a-lot |
→Research: added another clinical trial Tag: Reverted |
||
Line 146:
Selumetinib has also been shown to inhibit growth of ''[[GNAQ]]'' mutated uveal melanoma cell lines.<ref>{{cite journal | vauthors = Ambrosini G, Pratilas CA, Qin LX, Tadi M, Surriga O, Carvajal RD, Schwartz GK | title = Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance | journal = Clinical Cancer Research | volume = 18 | issue = 13 | pages = 3552–61 | date = July 2012 | pmid = 22550165 | pmc = 3433236 | doi = 10.1158/1078-0432.CCR-11-3086 }}</ref> Furthermore, preliminary results suggest that selumetinib treatment of uveal melanoma patients can result in tumor shrinkage as the consequence of sustained inhibition of [[:en:MAPK/ERK pathway|ERK]] [[:en:Phosphorylation|phosphorylation]].<ref>{{cite news | url = http://meetinglibrary.asco.org/content/101496-114 | title = Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma | date = 2012 }}</ref>
A [[Phase II clinical trial]] about selumetinib in NSCLC was completed in September 2011;<ref>{{cite journal | title=AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients | website=ClinicalTrials.gov | date=30 April 2009 | url=https://clinicaltrials.gov/ct2/show/NCT00890825 | access-date=10 April 2020}}</ref> one about cancers with ''[[BRAF (gene)|BRAF]]'' mutations is ongoing {{as of|2012|6|lc=on}}.<ref>{{cite journal | title=Selumetinib in Cancers With BRAF Mutations | website=ClinicalTrials.gov | date=27 April 2009 | url=https://clinicaltrials.gov/ct2/show/NCT00888134 | access-date=10 April 2020}}</ref> A Phase II trial investigating treatment of lung cancers with EGFR mutation is ongoing as of February 2022. </ref>{{ url=https://clinicaltrials.gov/ct2/show/NCT03392246?titles=Phase+2+study+of+osimertinib+in+combination+with+selumetinib+in+EGFR+inhibitor+naive+advanced+EGFR+mutant+lung+cancer&draw=2&rank=1}} </ref>
In July 2015, selumetinib failed a Phase III trial testing whether the drug significantly prolonged the survival of patients in a study on [[melanoma]] originating in the eye. In the 152-patient trial, a combination of selumetinib and [[dacarbazine]] failed to improve [[progression-free survival]] compared with just the old drug alone.<ref>{{cite press release | url=https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-selumetinib-uveal-melanoma-oncology-22072015.html | title=AstraZeneca provides update on selumetinib in uveal melanoma | website=AstraZeneca | date=22 July 2015 | access-date=10 April 2020}}</ref><ref>{{cite web|url=http://www.fiercebiotech.com/story/astrazenecas-once-lauded-drug-flunks-phase-iii-eye-cancer-trial/2015-07-22|title=AstraZeneca's once-lauded drug flunks a Phase III eye cancer trial|work=FierceBiotech}}</ref>
| |||